Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Don’t Miss

11 Sep 2023

News You Might Have Missed: Sep 11th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk
concordia

Industry

8 Sep 2023

Microdose Partners with Concordia for 2023 Annual Summit in New York City

Microdose is partnering with Concordia for the 2023 Concordia Annual Summit, taking place September 18-20 in New York City....

By Microdose NewsDesk
decrim

Law & Politics

7 Sep 2023

California Assembly Approves Psychedelics Legalization Bill

California is reaching the final stages of psychedelic legalization, as the California State Assembly passes a bill permitting the possession of certain psychedelics....

By Microdose NewsDesk
lab

Industry

7 Sep 2023

Awakn Life Sciences Submits Clinical Trial Application for Phase 3 Trial

Awakn Life Sciences has submitted a Clinical Trial Application for a phase III trial for its lead program for the treatment of Severe Alcohol Use Disorder....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

5 Sep 2023

Cybin Granted U.S. Patent for 5-MeO-DMT

The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs....

By Microdose NewsDesk

Don’t Miss

5 Sep 2023

News You Might Have Missed: Sep 5th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Science

1 Sep 2023

Usona Publishes Results of Phase 2 Psilocybin Trial for Depression

Results of the Usona Institute’s Phase 2 trial using psilocybin for depression were published yesterday....

By Microdose NewsDesk
mushroom deal

Breaking News

31 Aug 2023

Breaking News: Otsuka Pharmaceutical to Acquire Mindset Pharma

This morning we received news of Mindset Pharma being sold to a big pharma player, Otsuka Pharmaceutical....

By Microdose NewsDesk

Breaking News

28 Aug 2023

Breaking News: Cybin to Acquire Small Pharma

In big breaking news, Cybin has signed a deal to acquire Small Pharma, giving Cybin an advanced DMT trial....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.